Earnings ·
Reports Q3 net loss of $0.94 per share, cash position at $77.2M
VTVTvTv Therapeutics Inc.
vTv Therapeutics reported a third-quarter 2026 net loss attributable to shareholders of $11.6 million, or $0.94 per basic and diluted share, compared to an $8.7 million loss in the prior-year period. Cash and cash equivalents stood at $77.2 million as of September 30, 2026, down from $88.9 million a year earlier. The company highlighted that its Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes completed enrollment with 166 participants and expects topline results in mid-2027. Additionally, vTv randomized the first participant in its Phase 2a Hybrid CATT1 pilot study and received FDA Orphan Drug Designation for HPPD, a candidate for sickle cell disease. The late-stage biopharmaceutical company is focused on developing oral small-molecule therapies for diabetes and other chronic diseases.